Insight

Stephen V Liu: The 2024 IASLC Global Survey on Biomarker Testing is Available

Stephen V Liu/X

Aug 6, 2025, 21:34

Stephen V Liu: The 2024 IASLC Global Survey on Biomarker Testing is Available

Stephen V Liu, Chief of Division of Hematology and Oncology at Georgetown Lombardi Comprehensive Cancer Center, Director of Thoracic Oncology and Developmental Therapeutics, shared a post on X:

“Available JTO & JTO CRR – the 2024 International Association for the Study of Lung Cancer (IASLC) Global Survey on Biomarker Testing. Majority (67%) reported most patients had biomarker testing (up from 39% in 2018) but 43% sometimes treated before results. Barriers: cost, time, tissue, access, awareness.”

Balazs Halmos, Associate Director for Clinical Science at Montefiore Einstein Cancer Center, shared a post by Stephen V Liu, adding:

“Biomarker testing – comprehensive AND timely- is so pivotal in the proper management of NSCLC (now advanced and earlier stage alike)

Each team has to train hard for it to deliver the best results for our patients- dropping the baton 43% of the time is unacceptable! But when we get it done right- how exciting it is for the whole relay team – IP/IR/surg-path-mol path- med/rad onc to deliver the Olympic gold of optimal biomarker guided treatment for each patient.”

Title: The 2024 International Association for the Study of Lung Cancer (IASLC) Global Survey on Biomarker Testing

Authors: Matthew P. Smeltzer, Jennifer C. King, Casey Connolly, Kristin Brunson, Maiyan Chau, Shuyan Chen, Anna Kerpel-Fronius, Sylvie Lantuejoul, Anant Mohan, Allison Plaxco, Upal Basu Roy, Ricardo Santos, Ross Soo, Gavitt Woodard, Murry W. Wynes, Yasushi Yatabe, Amanda Young, Karen Kelly

Read the Full Article.

Stephen V Liu